The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: The house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet is a potential novel treatment option for HDM allergy-related asthma. OBJECTIVES: To evaluate the efficacy and adverse events of the HDM SLIT tablet vs placebo for asthma exacerbations during an inhaled corticosteroid (ICS) reduction period. DESIGN, SETTINGS, AND PARTICIPANTS: Double-blind, randomized, placebo-controlled trial conducted between August 2011 and April 2013 in 109 European trial sites. The trial included 834 adults with HDM allergy-related asthma not well controlled by ICS or combination products, and with HDM allergy-related rhinitis. Key exclusion criteria were FEV1 less than 70% of predicted value or hospitalization due to asthma within 3 months before randomization. Efficacy was assessed during the last 6 months of the trial when ICS was reduced by 50% for 3 months and then completely withdrawn for 3 months. INTERVENTIONS: 1:1:1 randomization to once-daily treatment with placebo (n = 277) or HDM SLIT tablet (dosage groups: 6 SQ-HDM [n = 275] or 12 SQ-HDM [n = 282]) in addition to ICS and the short-acting β2-agonist salbutamol. MAIN OUTCOMES AND MEASURES: Primary outcome was time to first moderate or severe asthma exacerbation during the ICS reduction period. Secondary outcomes were deterioration in asthma symptoms, change in allergen-specific immunoglobulin G4 (IgG4), change in asthma control or asthma quality-of-life questionnaires, and adverse events. RESULTS: Among 834 randomized patients (mean age, 33 years [range, 17-83]; women, 48%), 693 completed the study. The 6 SQ-HDM and 12 SQ-HDM doses both significantly reduced the risk of a moderate or severe asthma exacerbation compared with placebo (hazard ratio [HR]: 0.72 [95% CI, 0.52-0.99] for the 6 SQ-HDM group, P = .045, and 0.69 [95% CI, 0.50-0.96] for the 12 SQ-HDM group, P = .03). The absolute risk differences based on the observed data (full analysis set) in the active groups vs the placebo group were 0.09 (95% CI, 0.01-0.15) for the 6 SQ-HDM group and 0.10 (95% CI, 0.02-0.16) for the 12 SQ-HDM group. There was no significant difference between the 2 active groups. Compared with placebo, there was a reduced risk of an exacerbation with deterioration in asthma symptoms (HR, 0.72 [95% CI, 0.49-1.02] for the 6 SQ-HDM group, P = .11, and 0.64 [95% CI, 0.42-0.96] for the 12 SQ-HDM group, P = .03) and a significant increase in allergen-specific IgG4. However, there was no significant difference for change in asthma control questionnaire or asthma quality-of-life questionnaire for either dose. There were no reports of severe systemic allergic reactions. The most frequent adverse events were mild to moderate oral pruritus (13% for the 6 SQ-HDM group, 20% for the 12 SQ-HDM group, and 3% for the placebo group), mouth edema, and throat irritation. CONCLUSIONS AND RELEVANCE: Among adults with HDM allergy-related asthma not well controlled by ICS, the addition of HDM SLIT to maintenance medications improved time to first moderate or severe asthma exacerbation during ICS reduction, with an estimated absolute reduction at 6 months of 9 to 10 percentage points; the reduction was primarily due to an effect on moderate exacerbations. Treatment-related adverse events were common at both active doses. Further studies are needed to assess long-term efficacy and safety. TRIAL REGISTRATION: clinicaltrialsregister.eu Identifier: 2010-018621-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729
Self-citationDevelopment and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473
Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L.-P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-060st · Cited by 1,918
Determining a minimal important change in a disease-specific quality of life questionnaire
JUNIPER, E. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90036-1 · Cited by 1,824
Can Guideline-defined Asthma Control Be Achieved?: The Gaining Optimal Asthma ControL Study
Bateman, E. D., Boushey, H. A., Bousquet, J., Busse, W. W., Clark, T. J. H., Pauwels, R. A., & Pedersen, S. E. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200401-033oc · Cited by 1,594
Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy
Durham, S. R., Walker, S. M., Varga, E.-M., Jacobson, M. R., O'Brien, F., Noble, W., Till, S. J., Hamid, Q. A., & Nouri-Aria, K. T. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410702 · Cited by 1,373
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
World Medical Association (WMA) (2009) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/9783110208856.233 · Cited by 1,087
Jacobsen, L., Niggemann, B., Dreborg, S., Ferdousi, H. A., Halken, S., Høst, A., Koivikko, A., Norberg, L. A., Valovirta, E., Wahn, U., et al. (2007) · Allergy · doi:10.1111/j.1398-9995.2007.01451.x · Cited by 976
Baber, N. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb05705.x · Cited by 759
Validation of a Standardized Version of the Asthma Quality of Life Questionnaire
Juniper, E. F., Buist, A. S., Cox, F. M., Ferrie, P. J., & King, D. R. (1999) · Chest · doi:10.1378/chest.115.5.1265 · Cited by 714
Akdis, M., & Akdis, C. A. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.12.1088 · Cited by 565
Respiratory allergy caused by house dust mites: What do we really know?
Calderón, M. A., Linneberg, A., Kleine-Tebbe, J., De Blay, F., Hernandez Fernandez de Rojas, D., Virchow, J. C., & Demoly, P. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.012 · Cited by 553
Self-citationDurham, S. R., Emminger, W., Kapp, A., de Monchy, J. G. R., Rak, S., Scadding, G. K., Wurtzen, P. A., Andersen, J. S., Tholstrup, B., Riis, B., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.12.973 · Cited by 520
Self-citationBousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Ce, B.-C., Canonica, G. W., van Weel, C., et al. (2008) · Academic Production · Cited by 460
Self-citationMosbech, H., Deckelmann, R., de Blay, F., Pastorello, E. A., Trebas-Pietras, E., Andres, L. P., Malcus, I., Ljørring, C., & Canonica, G. W. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.03.019 · Cited by 285
Self-citationScadding, G. W., Shamji, M. H., Jacobson, M. R., Lee, D. I., Wilson, D., Lima, M. T., Pitkin, L., Pilette, C., Nouri‐Aria, K., & Durham, S. R. (2010) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2010.03462.x · Cited by 258
Overall asthma control: The relationship between current control and future risk
Bateman, E. D., Reddel, H. K., Eriksson, G., Peterson, S., Östlund, O., Sears, M. R., Jenkins, C., Humbert, M., Buhl, R., Harrison, T. W., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.033 · Cited by 258
Ragweed Immunotherapy in Adult Asthma
Creticos, P. S., Reed, C. E., Norman, P. S., Khoury, J., Adkinson, N. F., Buncher, C. R., Busse, W. W., Bush, R. K., Gadde, J., Li, J. T., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340804 · Cited by 241
Demoly, P., Emminger, W., Rehm, D., Backer, V., Tommerup, L., & Kleine-Tebbe, J. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.06.036 · Cited by 240
Self-citationBergmann, K.-C., Demoly, P., Worm, M., Fokkens, W. J., Carrillo, T., Tabar, A. I., Nguyen, H., Montagut, A., & Zeldin, R. K. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.11.012 · Cited by 208
A note on the power of Fisher's least significant difference procedure
Meier, U. (2006) · Pharmaceutical Statistics · doi:10.1002/pst.210 · Cited by 197
Zielen, S., Kardos, P., & Madonini, E. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.06.002 · Cited by 162
Nolte, H., Maloney, J., Nelson, H. S., Bernstein, D. I., Lu, S., Li, Z., Kaur, A., Zieglmayer, P., Zieglmayer, R., Lemell, P., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1911 · Cited by 160 · cited 2×
“Previous smoker 36 (13) 50 (18) 38 (13) 124 (15)”
Self-citationBousquet, J. J., Khaltaev, N., Cruz, Ã. A., Denburg, J. A., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., van Weel, C., et al. (2008) · Cited by 106
Self-citationMosbech, H., Canonica, G. W., Backer, V., de Blay, F., Klimek, L., Broge, L., & Ljørring, C. (2015) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2014.11.015 · Cited by 86
Self-citationLong-term clinical and immunological effects of allergen immunotherapy
Eifan, A. O., Shamji, M. H., & Durham, S. R. (2011) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e32834cb994 · Cited by 86
Blumberga, G., Groes, L., Haugaard, L., & Dahl, R. (2006) · Allergy · doi:10.1111/j.1398-9995.2006.01088.x · Cited by 85
SQ HDM SLIT-tablet (ALK) in treatment of asthma – Post hoc results from a randomised trial
Frederic de, B. L. A. Y., Kuna, P., Prieto, L. M., Ginko, T., Seitzberg, D., Riis, B., & Canonica, G. W. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.07.017 · Cited by 74
Self-citationDefining moderate asthma exacerbations in clinical trials based on ATS/ERS joint statement
Virchow, J. C., Jr., Backer, V., Frederic de, B. L. A. Y., Kuna, P., Ljørring, C., Prieto, J. L., & Villesen, H. H. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.01.012 · Cited by 65
Self-citationKupczyk, M., Kuprys-Lipinska, I. R., Górski, P., & Kuna, P. (2004) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)61782-6 · Cited by 44
Self-citationMometasone furoate/formoterol reduces asthma deteriorations and improves lung function
Meltzer, E. O., Kuna, P., Nolte, H., Nayak, A. S., & LaForce, C. (2011) · European Respiratory Journal · doi:10.1183/09031936.00020310 · Cited by 40
Self-citationBurden of rhinitis in children with asthma
Kocabaş, C. N., Civelek, E., Saçkesen, C., Orhan, F., Tuncer, A., Adalıoğlu, G., & Şekerel, B. E. (2005) · Pediatric Pulmonology · doi:10.1002/ppul.20247 · Cited by 36
Rønborg, S., Johnsen, C. R., Theilgaard, S. A., Winther, A., Hahn-Pedersen, J. H., Andreasen, J. N., & Olsen, J. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2016.1158718 · Cited by 17
Cited by
Bousquet, J., Anto, J. M., Bachert, C., Baiardini, I., Bosnic-Anticevich, S., Walter Canonica, G., Melén, E., Palomares, O., Scadding, G. K., Togias, A., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00227-0 · Cited by 942
Cloutier, M. M., Baptist, A. P., Blake, K. V., Brooks, E. G., Bryant-Stephens, T., DiMango, E., Dixon, A. E., Elward, K. S., Hartert, T., Krishnan, J. A., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.10.003 · Cited by 854
EAACI Guidelines on Allergen Immunotherapy: Allergic Rhinoconjunctivitis
Roberts, G., Pfaar, O., Akdis, C. A., Ansotegui, I. J., Durham, S. R., Gerth van Wijk, R., Halken, S., Larenas‐Linnemann, D., Pawankar, R., Pitsios, C., et al. (2018) · Allergy · doi:10.1111/all.13317 · Cited by 702
Porsbjerg, C., Melén, E., Lehtimäki, L., & Shaw, D. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02125-0 · Cited by 575
Chu, D. K., Wood, R. A., French, S., Fiocchi, A., Jordana, M., Waserman, S., Brożek, J. L., & Schünemann, H. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30420-9 · Cited by 448
Metadata
- Authors
- Virchow, J. C., Backer, V., Kuna, P., Prieto, L., Nolte, H., Villesen, H. H., Ljørring, C., Riis, B., & de Blay, F.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-04-26
- Volume
- 315
- Issue
- 16
- Pages
- 1715
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2344044328
- Cited by
- 436
- References
- 34
- FWCI
- 45.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.